Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial

Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) improve survival in castration-resistant prostate cancer (CRPC). However, which agent is better for CRPC patients remains unclear. The enzalutamide versus abiraterone plus prednisolone before chemotherapy for castration-resistant prostate cancer study (ENABLE study for PCa) is a head-to-head comparison between ENZ and ABI in this population. ENZ did not show any further survival benefit in comparison to ABI, but showed a better prostate-specific antigen response rate with a low rate of severe adverse events, suggesting that use of ENZ before ABI has potential clinical benefits in CRPC.